# Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

> **NCT05959083** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 200 (actual)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05959083
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05959083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05959083, "Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05959083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*